An observational study in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 19 sites in Korea, Republic of. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-21.
Sponsored by Ferring Pharmaceuticals · Observational
The purpose of this study is to evaluate the safety and efficacy of highly purified (HP) menotrophine to Korean women.
2,506 studies on the registry are indexed under Infertility; 407 are open to participants now.
This study's enrollment of 2,501 is above the median of 200 across 714 observational studies indexed under Infertility.
Browse Infertility studies →Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
Infertile women
Exclusion Criteria:
Number of follicles per cycle
An ART cycle: From ovulation (number and size) to when chemical pregnancy test results are recorded
Time frame: Up to 6 weeks
Number of adverse events
An ART cycle: From ovulation (number and size) to when chemical pregnancy test results are recorded
Time frame: Up to 6 weeks
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ferring Pharmaceuticals